Thinking of joining a study?

Register your interest

NCT04209829 | Not yet recruiting | Hematologic Diseases


Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics
Sponsor:

Assistance Publique - Hôpitaux de Paris

Brief Summary:

Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells, T cells whose receptor has been genetically modified, is based on improving the immune response against the tumor. This approach is promising for patients with hematologic malignancies refractory to chemotherapy. Despite impressive results, too many patients are relapsing. The reasons for the relapse, after the injection of CAR T cells, need to be explored. In this context of newly introduced therapeutics, it is essential to better understand the factors associated with the response to treatment with CAR T Cells, especially the characteristics of the tumor and its microenvironment. The objective of this study is to understand the role of tumor biology, and its microenvironment, in the response to CAR-T Cells therapy in patients with hematologic malignancies

Condition or disease

Hematologic Diseases

Study Type : Observational
Estimated Enrollment : 600 participants
Official Title: Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies (Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma) Depending on Tumor Characteristics
Actual Study Start Date : December 2019
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2035

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 15 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • patient with hematological malignancy (lymphoma, ALL, MM)
  • patient integrated into a CAR-T Cells program treatment
  • patient aged 15 years or over
  • patient having signed a written consent; as well as his legal representative if <18 years old
Exclusion Criteria
  • patient with other hematological malignancies than lymphoma, LAL or MM
  • patient's weight <58 kg
  • patient treated with another treatment than CAR-T Cells
  • patient under tutorship or curatorship
  • patient not covered by a health system

Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics

Location Details


Please Choose a site



Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Loading...